Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...

Doctors in the US have treated a fetus with a rapidly progressive congenital disease from inside the womb for the very first ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

Figures from the Social Insurance Institution (Kela) reveal a staggering rise in prescriptions for ADHD medication, with ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

The Taylor Sheridan Expanded TV Universe is full of tough-talking hombres—manly men who wear cowboy hats and stern frowns. In Yellowstone, the Duttons operate almost like a crime family, willing to do ...

Some widely used medications may have significant cognitive effects, both positive and negative, according to a new study.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

European stocks are soaring as American markets stay choppy. With more European military spending on the horizon, defense ...

We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...